Ann Geriatr Med Res Search


Ann Geriatr Med Res > Volume 24(2); 2020 > Article
Dzhus, Dzhus, Masnyi, Kulyk, Mostbauer, Ivashkivsky, Boyko, Cherchenko, Geerinck, Reginster, Bruyere, and Beaudart: Cross-sectional Evaluation of the Sarcopenia Quality of Life (SarQoL) Questionnaire: Translation and Validation of its Psychometric Properties



The SarQoL, a quality-of-life questionnaire specific to sarcopenia, was developed in 2015 and has since been translated into a number of other languages. The main reason to introduce this new Ukrainian version of the questionnaire was to measure sarcopenic individuals’ perceptions regarding their positions in life in the context of their culture and value systems.


The questionnaire was translated using a forward-backward approach with a pre-test. A total of 49 participants were recruited for the validation study. Sarcopenia was diagnosed according to the Ishii test. The validation analyses included discriminative power, internal consistency, floor and ceiling effects, construct validity, and test-retest reliability. We compared the SarQoL questionnaire to the Short-Form 36 and the EuroQoL-5 Dimensions.


A total of 28 participants out of 49 were categorized as probably sarcopenic. They had a significantly lower quality of life (overall score 58.43±17.13 vs. 69.89±13.31; p=0.014). The internal consistency was excellent (α=0.898), with none of the domains showing a disproportionate influence on the homogeneity of the questionnaire. Convergent construct validity was also confirmed. The results indicated a near-perfect degree of test-retest reliability.


The first Ukrainian version of the questionnaire is equivalent to the available original English version.


Sarcopenia is a progressive and generalized loss of muscle mass and function with advancing age.1,2) This geriatric syndrome is now considered an increasing public health issue worldwide.3) Sarcopenia is associated with adverse health outcomes such as physical impairment, mobility limitations, increased fall risk, hospitalization, and mortality.4) In the last decade, several sarcopenia definitions and proposals for diagnostic criteria have been published. Among these, the revised consensus criteria of the European Working Group on Sarcopenia in Older People (EWGSOP2) appear to be the most promising. The EWGSOP2 considers sarcopenia to be present when a person presents with both low muscle strength and low muscle mass. Additionally, people with low physical performance are categorized as severely sarcopenic.3)
This condition can also impact patient quality of life. Since this aspect is not straightforward for clinical evaluation, the issue is less studied so far. The existing quality of life questionnaires, such as the Short Form 36 (SF-36) and EuroQoL 5-dimension (EQ-5D), are designed for use in a broad swath of health conditions and patient populations and, thus, do not cover all physical dysfunctions associated with sarcopenia. Consequently, it would be useful to have a specific questionnaire to assess the impact of sarcopenia on quality of life.
The SarQoL questionnaire is the first multidimensional disease-specific questionnaire designed for community-dwelling sarcopenic subjects aged 65 years and older. It comprises 22 questions rated on a 3-, 4-, or 5-point Likert scale. Items are categorized into the following sevens domains of dysfunction: physical and mental health, locomotion, body composition, functionality, activities of daily living, leisure activities, and fears. The questionnaire was initially developed and validated in French in 20155,6) and was later translated and validated into English, Dutch, Romanian, Polish, Hungarian, Russian, and Greek.7-13)
To provide the Ukrainian nation with a qualitative and reliable questionnaire to measure the quality of life of sarcopenic patients, we have created the Ukrainian version of the SarQoL questionnaire. The process of translation and validation followed the protocol for translation provided by the authors of the SarQoL questionnaire, which were based on the recommendations of Beaton et al.14) This protocol included translation, cross-cultural adaptation, and validation of psychometric properties of the questionnaire. This process ensures standardization of the translated versions and makes them valid instruments for clinical purposes.
The objectives of this study were to translate the SarQoL questionnaire from English into Ukrainian and to assess its main psychometric properties.


Ukrainian Translation

The translation was performed by a group of experts to exclude any cultural divergence and ensure the usefulness of the questionnaire in different populations. The process of translation from English to Ukrainian and cross-cultural adaptation was performed according to specific guidelines14) and included five phases: (1) independent forward translation by two bilingual translators (one of whom had a medical background; the other was a novice regarding the topic of questionnaire), both native Ukrainian speakers; (2) synthesis of the initial translations providing a single “Version 1”; (3) independent backward translations of “Version 1” from Ukrainian to English by two bilingual translators who were native English speakers, had no medical background, and were blind to the original version of the SarQoL questionnaire; (4) comparison of the Version 1 and backward translations by an expert committee, resulting in a pre-final version of the Ukrainian SarQoL questionnaire and a full written report of the issues encountered at each step; and (5) a test of the pre-final version on 10 sarcopenic subjects to ensure understanding of the purpose and meaning of each question, which led to the final version of the SarQoL-UA.
The translation was performed with the permission of the rights holder of the SarQoL questionnaire (SarQoL sprl, Brussel, Belgium); the original developers also provided assistance and advice during the translation and validation process. The original developers of the questionnaire (OB and CB) were kept informed of the major choices made during the translation process and the results of the pre-test of the questionnaire and confirmed the equivalence between the English and Ukrainian versions.


Participants and protocol

A total of 49 patients aged 65 years and older were recruited in Oleksandrivska Clinical Hospital in Kyiv, Ukraine, where large proportions of older and geriatric patients are treated.
All patients were informed about the objective and form of subsequent questions and tests before providing their informed consent. Patients with severe exacerbations of chronic illnesses, decompensations of heart failure and diabetes, physical malformations, or traumas associated with decreased mobility, amputations, malignant diseases, and also mental illnesses that prevented understanding and correct response to the questions were not included in the investigation. The study was approved by the Ethics Committee of Oleksandrivska Clinical Hospital (No. 22/2016). We collected clinical and demographic variables such as age, sex, body mass, height, waist, hip and thigh circumference, muscle strength, and gait speed using standard methods by trained examiners. Due to limited access to dual-energy X-ray absorptiometry (DEXA) equipment, the probability of sarcopenia was determined using the Ishii screening test.15) The objective of this test is to identify older adults at a high risk of sarcopenia; the test relies on a combination of age, grip strength, and calf circumference. The exact formulas are as follows:
Score in men = 0.62×(age 64 y) – 3.09×(grip strength 50 kg) – 4.64×(calf circumference 42 cm)
Score in women = 0.80×(age 64 y) – 5.09×(grip strength 34 kg) – 3.28×(calf circumference 42 cm)
The established cutoff values that maximize the sum of sensitivity and specificity are ≥105 for men and ≥120 for women,3) with higher scores indicating an increased probability of sarcopenia.
Muscle strength was evaluated based on handgrip strength measured using a manual spring dynamometer (DRP-90, GOST 22224-76, Russia) with a cutoff value of <20 kg for women and <30 kg for men. The measurements were performed on both the patients’ dominant and non-dominant hands, with the highest value recorded. To evaluate physical performance, we used gait speed in the form of the 3-minute timed walk test. The patients were asked to walk at their standard speed and the mean of the meters walked was converted to speed in meters per second (m/s) for analysis. Values <0.8 m/s indicated poor physical performance.16)


Psychometric validation of the Ukrainian version of the SarQoL

Validation of the psychometric properties of the SarQoL-UA consisted of an assessment of its discriminative power, internal consistency, potential floor and ceiling effects, construct validity, and test-retest reliability, all of which were performed according to the recommendations of Terwee et al.17)
(1) Discriminative power, also called known-groups validity, was evaluated by comparing the QoL scores between participants who were categorized as probably having sarcopenia by the Ishii test and those categorized as probably not having sarcopenia. Additionally, we examined two components of sarcopenia, grip strength and gait speed, by comparing subjects with low and normal values. The sample was dichotomized using the EWGSOP2 cutoffs (<27 kg for men and <16 kg for women for grip strength and ≤0.8 m/s for gait speed).3) To assess the discriminative power of the questionnaire, we assumed that the QoL scores should be higher (indicating better QoL) in population categorized as probably non-sarcopenic, or with normal grip strength or gait speed, compared to those categorized as probably sarcopenic or with low grip strength or gait speed.
(2) Internal consistency. To measure internal consistency, understood as an estimation of the questionnaire’s homogeneity, we calculated the Cronbach’s alpha coefficient.18) A coefficient value between 0.7 and 0.9 indicates a high level of internal consistency. By deleting one domain at a time, we also considered the impact of each domain on internal consistency. The correlation of each domain with the total SarQoL-UA score was also assessed by correlation analysis. We defined excellent correlation as r>0.81, very good correlation as r between 0.61 and 0.80, and good correlation as r between 0.41 and 0.60.
(3) Floor and ceiling effects are present when a high percentage of the population has the lowest or the highest scores, respectively. We considered significant floor and ceiling effects when higher than 15%.
(4) Construct validity. The construct validity of the questionnaire indicates whether the questionnaire measures the construct it claims to measures. This was investigated by measuring the convergent and divergent validity; i.e., the level of agreement between the SarQoL questionnaire and domains of other questionnaires that are theorized to be similar or different. Every patient completed, at the same time as the SarQoL-UA questionnaire, the SF-36v2 and the EQ-5D, two generic QoL questionnaires. The generic SF-36 questionnaire (SF-36v2)19) contains 36 items in eight health domains. Two components of the health survey were calculated: the physical component summary (PCS) and the mental component summary (MCS), providing reliable and valid summaries of a patient’s physical and mental status. The total raw score computed for each health domain scale was calculated, in which 0 and 100 points indicated the worst and best QoL, respectively.20)
For the evaluation of overall self-rated health status, we used the EQ-5D questionnaire,21) which includes five domains: mobility, usual activities, self-care, pain/discomfort, and anxiety/depression, as well as the EQ Visual Analogue Scale (EQ-VAS).22) Each of the five dimensions comprising the EQ-5D was divided into five levels of perceived impairment, from level 1 (no problem) to level 5 (extreme problems). A unique health state was defined by combining the reported level from each of the five dimensions and referring the result to a five-digit code that was subsequently converted to a single index value (EQ-5D index value).23)
For convergent construct validity, we hypothesized strong correlations between the overall QoL SarQoL score and the mobility and usual activities questions of the EQ-5D, as well as with the SF-36 PCS and the EQ-VAS. For divergent construct validity, we expected to find weak or non-existent correlations between the overall QoL SarQoL score and the self-care, pain/discomfort, and anxiety/depression questions of the EQ-5D, as well as the SF-36 MCS.
(5) Test-retest reliability. The test-retest reliability of the questionnaire, defined as the degree to which the questionnaire produces the same results in identical circumstances over time, was evaluated by intra-class correlation coefficient (ICC). To analyze the test-retest stability of our Ukrainian version of the SarQoL, participants who did not report any significant health change over a 2-week period were asked to complete the questionnaire again after a 2-week interval. The reliability was considered acceptable for ICC>0.7.

Statistical Analysis

The distribution of quantitative variables was assessed using Shapiro-Wilk tests. Quantitative variables with a normal distribution are expressed as mean±standard deviation, and quantitative variables with non-normal distributions are expressed as medians (P25–P75) and categorical variables are reported as absolute (n) and relative frequencies (%). Results were considered statistically significant at the 5% critical level (p<0.05).
Differences in characteristics between groups were tested using the parametric Student t-test or the non-parametric Mann-Whitney U-test for quantitative variables and chi-square tests for nominal variables. For internal consistency, the Cronbach's alpha coefficient was calculated. The correlation of each domain with the total score of the SarQoL-UA was determined using Pearson or Spearman correlations based on the distribution of the variables. The evaluation of the construct validity also used Pearson or Spearman correlations. The test-retest reliability was assessed using ICC (two-way mixed-absolute agreement). All of the analyses were performed using IBM SPPS Statistics version for Windows (IBM, Armonk, NY, USA).



No major conceptual discrepancies were observed between translations and all differences were resolved by consensus. We reached out to CB and OB for clarification on the content of certain questions, to make sure that the translated questions were conceptually equivalent to the questions in English. The 22 questions of the SarQoL questionnaire were translated without any major difficulties. Certain adaptions were made to optimize the questionnaire for the cultural context of Ukraine, such as discussion regarding the forward translation of the words “light” (in question 3) and “moderate” (in question 4), “frail” (in question 16) and “do it yourself (DIY)” (in question 3), which were solved in the initial translators’ meeting. A pretest in the third and prefinal version was performed on 20 participants.
The pre-test did not reveal problems in the comprehensibility of the questions in the questionnaire or the language used therein.

Sample Characteristics

In the study population, median age was 71 years (range, 67.0-75.5 years) (Table 1), including 29 (59.2%) men and 20 (40.8%) women. The study population were overweight, with a median body mass index of 29.06 kg/m2 (range, 25.28–32.62 kg/m2).
We observed that both male and female participants had low grip strength, as evidenced by the fact that 70% of the female subjects and 65.5% of male subjects had low maximum grip strengths according to the EWGSOP2 cutoffs. For physical performance, represented by gait speed, we observed a mean value of 0.95±0.37 m/s, well above the ≥0.8 m/s threshold used by the EWGSOP2 to indicate low gait speed.
We divided the patients into two groups according to the probable presence or absence of sarcopenia, as indicated by Ishii test results. A total of 28 and 21 people were probably sarcopenic and probably non-sarcopenic, respectively. As expected, age, grip strength, and calf circumference differed between the two groups. Although the median gait speed was considerably higher is the probably non-sarcopenic group (1.2 vs. 0.8 m/s), the difference was not significant (p=0.056).

Validation Analyses

Discriminative power

The discriminative power was examined by comparing the quality of life scores between the people classified as probably and probably non-sarcopenic according to the Ishii screening test (Table 2).
Additionally, a discriminative power analysis was also performed by dichotomizing the people by grip strength (men <27 kg; women <16 kg) and gait speed (≥0.8 m/s).
Categorization of the patients into probably and probably non-sarcopenic according to the Ishii test showed significantly lower quality of life scores for five of the seven of the domain scores, as well as the overall QoL score (58.43±17.13 vs. 69.89±13.31 points; p=0.014).
In contrast, no significant differences were found for the SF-36 PCS and MCS summary scores, as well as for the EQ-VAS. Examination of the individual questions of the EQ-5D showed that participants in the probably sarcopenic group scored higher on the pain/discomfort item, indicating more pain/discomfort and thus worse QoL—3 (2–3) vs. 2 (1–3); p=0.032. The other EQ-5D items did not differ significantly between the two groups.
We observed that people with low grip strength or low gait speed generally showed lower quality of life scores on the SarQoL questionnaire, except for domains 6 and 7. Crucially, the overall QoL score was significantly lower for people with low grip strength (56.71±16.96 vs. 68.73±15.33 points; p=0.0169) and people with low gait speed (49.93±12.23 vs. 73.40±11.29; p<0.001). The results for all domains are reported in Tables 3 and 4.

Internal Consistency

Cronbach’s alpha coefficient

The complete questionnaire showed an alpha of 0.898; the value within the 0.7–0.9 threshold indicated adequate internal consistency with a low risk of redundancy in the questionnaire. Deletions of single domains showed Cronbach’s alpha values ranging from 0.861 to 0.912, indicating that no domain had a disproportionate influence on the homogeneity of the questionnaire (Table 5).

Correlations between overall and individual domain scores

The correlations between each domain and the total score of the SarQoL questionnaire were also assessed using Spearman coefficients. All domains showed a strong significant positive correlation with the overall score of the SarQoL, except for domain 6 (Table 5).

Floor and Ceiling Effects

No participants (n=49) presented with the lowest score to the questionnaire (0 points) or the maximal score (100 points) on the Overall QoL score. A ceiling effect was present for domain 7, where 14 people (28.6%) scored 100 points.

Construct Validity

Assessment of the convergent validity in the complete sample showed three strong and significant and one moderate and significant correlation, confirming the convergent validity of the Ukrainian SarQoL questionnaire (Table 6). Assessment of the divergent validity showed two strong and one moderate correlation (Table 6).
Analysis of the 28 participants categorized as probably sarcopenic showed good convergent validity, with four strong correlations but inadequate divergent construct validity.

Test-Retest Reliability

The test-retest reliability indicated near-perfect results (Table 7), with an ICCs of 0.997 (0.994–0.998) for the overall quality of life score of the SarQoL questionnaire in the complete sample and 0.998 (0.995–0.999) in the probably-sarcopenic group. The lowest ICC was observed in the analysis of the probably-sarcopenic sample, in which domain 6 showed an ICC of 0.912 (0.821–0.958), still considered to be an excellent degree of test-retest reliability.
The rest-retest reliabilities of the SF36 PCS and MCS scores were of the same order as that of the SarQoL (ICC>0.9) and slightly lower in the EQ-VAS (ICC=0.829 for the complete sample and 0.876 in the probably-sarcopenic sample). However, the test-retest reliability of the EQ-VAS in this sample was still considered acceptable, as it was above the cutoff of 0.7.


The results of our study showed that the Ukrainian version of the original SarQoL is a valid and discriminant questionnaire that is useful to determine the quality of life of patients with sarcopenia. The SarQoL is the first quality of life questionnaire specific to sarcopenia available in the Ukrainian language. The population of Ukraine is 43 million, of whom 6.9 million (15.32%) are aged over 65 years;24) thus, the SarQoL-UA questionnaire can be a reliable, and cost-effective tool for assessing QoL among older Ukrainian patients possibly affected by sarcopenia.
Because of the cost and complexity of measuring muscle mass using a DEXA instrument, we used the Ishii screening test16) to screen patients for sarcopenia, which is much easier, faster, and cheaper and does require a specific apparatus. The Ishii test has excellent sensitivity and specificity compared with to other diagnostic definitions of sarcopenia such as the two-step algorithm of the EWGSOP, the SARC-F questionnaire, the screening grid, and the anthropometric prediction equation.15) We observed that people with low grip strength or gait speed generally showed lower quality of life scores on the SarQoL questionnaire (except for domains 6 and 7), which might be because these domains have low numbers of items (and thus less precision) in combination with a relatively low number of study population.
Similar publications of validations of the SarQoL are available for the English, French, Dutch, Romanian, Polish, Lithuanian, Greek, and other language versions,7-10,13,25) with similar results in terms of the reliability and validity of the SarQoL questionnaire.
The Cronbach’s alpha of the Ukrainian version of the SarQoL was 0.898. The recommended values are 0.7–0.9, with an upper limit of 0.95.17,26) The Cronbach’s alpha value in our study is similar to those reported for the French, English, and Dutch versions (0.87, 0.88, and 0.883, respectively).5,7,8) The alpha value in our study was lower than those in the Greek, Lithuanian, Romanian, and Polish validation studies (0.960, 0.950, 0.946, and 0.920, respectively) suggesting that some questions in the SarQoL may be redundant.9,10,13,25) However, although the internal consistency of the Ukrainian was excellent, this does not mean that cross-cultural effects are, therefore, excluded. Although we paid particular attention to cross-cultural equivalence, Ukrainian participants may have responded differently to certain questions. We hope that the data from this study and future data collected with the SarQoL-UA can be used in combination with data from other countries to analyze the questionnaire with Item Response Theory to detect any differential item functioning effects.
Test-retest reliability was excellent in our study and the same as reported in French, English, Dutch, Polish, Greek and Lithuanian studies.6-8,10,13,25) The validation of the Romanian version did not perform test-retest reliability because of the limited number of sarcopenic subjects (n=13). Overall, the results have indicated that the SarQoL questionnaire is a reliable instrument.25)
The construct validity of the SarQoL-UA was examined with eight hypotheses on the correlation between the domains of the SF-36 and EQ-5D questionnaires that were theorized to measure a similar (convergent) or dissimilar (divergent) construct from that of the SarQoL-UA. The results showed that the questionnaire possessed good convergent validity; however, the results of the divergent validity were not as expected. It may be that the constructs represented in the SF-36 MCS and the self-care and pain/discomfort items of the EQ-5D are more closely aligned with the overall quality of life, the construct measured by the SarQoL-UA.
The major limitation of our study was related to the absence of a muscle mass assessment because we were not able to determine appendicular muscle mass using DEXA. In our study group, sarcopenia status was estimated using the Ishii equation (described above). However, anthropometric measurements are prone to errors and may produce pitfalls; thus, they are not recommended for routine use according to the EWGSOP.3) Nevertheless, the equation provided by Ishii et al. for the estimation of sarcopenia was previously validated and showed a high level of corresponding sensitivity, specificity, positive and negative predictive values, and positive and negative likelihood ratios (84.9%, 88.2%, 54.4% and 97.2%, and 7.19 and 0.17 for men and 75.5%, 92.0%, 72.8% and 93.0%, and 9.44 and 0.27 for women, respectively).16) A second possible limitation was the low number of participants. Although there are no fixed requirements for minimum sample size in validation studies, a commonly used benchmark is a sample of 100 participants, of whom 50 should have the condition in question.17) The present study included a total of 49 participants, 28 of whom were probably sarcopenic based on the Ishii test; however, because of the relative precision of the obtained values (i.e., small standard deviations or 95% confidence intervals), we obtained statistically significant results in most if not all of our analyses. While this study falls short of the arbitrary sample size of 100 participants, the results should not be discounted given the significant p-values obtained throughout.
In summary, this first Ukrainian version of the SarQoL questionnaire is equivalent to the available original version. Thus, this tool may be used for clinical and research purposes. This questionnaire had higher sensitivity than that of other standard QoL questionnaires. The availability of the SarQoL questionnaire to the Ukrainian scientific community gives physicians speaking this language the chance to better follow and monitor sarcopenic patients in Ukraine. Thus, the Ukrainian version of SarQol may be potentially incorporated in the routine geriatric curriculum designated for the assessment of sarcopenic Ukrainian-speaking individuals.


We thank Pr. JY Reginster, Pr. O Bruyère, and Pr. C Beaudart for their permission to adapt the questionnaire to a Ukrainian setting and for their help and advice during this process.



OB, JYR, and CB are shareholders of SarQoL sprl. The authors declare no conflict of interest. The study was conducted in the absence of any financial or other relationships that could be construed as a potential conflict of interest.


Conceptualization, JYR; Methodology, MD, CB, OB; Validation, MD-Jr, KCh, MK, MM, and HM; Formal analysis, MB, AG; Investigation, ET, LM, MD; Resources: OB, JYR; Data curation: MD-Jr, KG; Writing-original draft, MD; Writing-review and editing, MD, CB; Supervision, OB, JYR, CB.

Table 1.
Clinical characteristics of the patients
Variable All (n=49) Probably sarcopenic (n=28) Probably non-sarcopenic (n=21) p-value
Age (y) 71.00 (67.00–77.50) 73.50 (68.50–79.00) 69.00 (67.00–73.50) 0.046a)
Sex 0.737b)
 Female 20 (40.8) 12 (42.9) 8 (38.1)
 Male 29 (59.2) 16 (57.1) 13 (61.9)
BMI (kg/m²) 29.06 (25.28–32.62) 28.00 (25.64–32.28) 30.91 (24.33–34.65) 0.391a)
Calf circumference (cm) 37.00 (33.75–40.00) 35.75 (33.00–38.38) 39.00 (35.50–41.50) 0.016a)
Maximum grip strength (kg) 16 (8.00–25.50) 9 (6.25–15.00) 30 (19.50–33.00) <0.001a)
Gait speed (m/s) 0.95 (0.65–1.26) 0.80 (0.59–1.22) 1.20 (0.71–1.36) 0.056a)

Values are presented as median (25th percentile–75th percentile) or number (%).

BMI, body mass index.

a) Mann–Whitney U-test,

b) Chi-square test.

Table 2.
Quality of life characteristics
Variable All (N=49) Probably sarcopenic (n=28) Probably non-sarcopenic (n=21) p-value
SarQoL D1 Physical and mental health 59.97 (47.20–72.75) 56.72±16.63 66.43±16.85 0.050a)
SarQoL D2 Locomotion 66.67 (47.22–86.11) 56.95 (33.34–87.50) 72.22 (58.33–87.50) 0.069b)
SarQoL D3 Body composition 58.33 (41.67–75.00) 43.75 (37.50–66.67) 66.67 (56.25–75.00) 0.010b)
SarQoL D4 Functionality 71.15 (49.04–85.17) 62.85±18.61 77.24±14.18 0.005a)
SarQoL D5 Activities of daily living 61.67 (43.10–76.67) 55.15±19.84 66.18±16.14 0.043a)
SarQoL D6 Leisure activities 33.25 (33.25–49.88) 41.57 (33.25–49.88) 33.25 (33.25–49.88) 0.366b)
SarQoL D7 Fears 87.50 (75.00–100) 87.50 (75.00–87.50) 87.50 (87.50–100) 0.016b)
SarQoL Overall QoL 63.72 (45.96–79.24) 58.43±17.13 69.89±13.31 0.014a)
SF-36 PCS 36.00 (27.00–43.50) 34.14±10.85 38.19±8.94 0.171a)
SF-36 MCS 47.40 (39.93–53.78) 48.17±10.28 44.36±9.67 0.194a)
EQ-5D Mobility 2 (1–3) 2 (1.25–3) 2 (1–2) 0.092b)
EQ-5D Self-care 1 (1–2) 1 (1–2) 1 (1–1) 0.211b)
EQ-5D Usual activities 2 (1–3) 2 (1–3) 1 (1–2) 0.137b)
EQ-5D Pain/discomfort 2 (2–3) 3 (2–3) 2 (1–3) 0.032b)
EQ-5D Anxiety/depression 2 (1–2) 2 (1–2) 1 (1–3) 0.870b)
EQ-VAS 50 (50.00–65.00) 50 (46.25–65.00) 55 (50.00–65.00) 0.592b)

Values are presented as median (25th percentile–75th percentile) or mean±standard deviation.

EQ-5D, EuroQoL 5-dimension; PCS, physical component summary; MCS, mental component summary; VAS, visual analog scale.

a) Student t-test,

b) Mann–Whitney U-test.

Table 3.
Discriminative power for grip strength
Low grip strength (n=32) Normal grip strength (n=17) p-value
SarQoL D1 Physical and mental health 56.71±16.96 68.73±15.33 0.019a)
SarQoL D2 Locomotion 58.33±24.00 75.49±18.46 0.014a)
SarQoL D3 Body composition 43.75 (37.50–65.63) 75.00 (60.42–79.17) 0.001b)
SarQoL D4 Functionality 63.53±18.07 79.34±13.61 0.003a)
SarQoL D5 Activities of daily living 54.17 (38.75–72.08) 73.33 (62.98–80.00) 0.008b)
SarQoL D6 Leisure activities 33.25 (33.25–49.88) 33.25 (33.25–49.88) 0.973b)
SarQoL D7 Fears 87.50 (75.00–87.50) 87.50 (87.50–100) 0.080b)
Overall score 58.30±16.31 72.82±12.37 0.002a)

Values are presented as mean±standard deviation or median (25th percentile–75th percentile).

a) Student t-test for independent samples,

b) Mann–Whitney U-test.

Table 4.
Discriminative power for gait speed
Low gait speed (n=21) Normal gait speed (n=28) p-value
SarQoL D1 Physical and mental health 51.04±12.18 68.27±16.94 <0.001a)
SarQoL D2 Locomotion 44.44 (27.78–62.50) 79.17 (63.89–94.44) <0.001b)
SarQoL D3 Body composition 41.67 (35.42–54.17) 72.92 (58.33–83.33) <0.001b)
SarQoL D4 Functionality 56.07±16.25 78.72±12.80 <0.001a)
SarQoL D5 Activities of daily living 43.33 (35.42–54.17) 75.00 (65.00–80.00) <0.001b)
SarQoL D6 Leisure activities 33.25 (24.94–49.88) 41.57 (33.25–49.88) 0.081b)
SarQoL D7 Fears 87.50 (75.00–87.50) 87.50 (78.13–100) 0.084b)
Overall score 49.93±12.23 73.40±11.29 <0.001a)

Values are presented as mean±standard deviation or median (25th percentile–75th percentile).

a) Student t-test for independent samples.

b) Mann–Whitney U-test.

Table 5.
Correlations between overall and domain scores and Cronbach’s alpha
Correlations between overall and domain scores (n=48) Cronbach’s alpha if domain deleted (n=49) Overall Cronbach’s alpha
r p-value
SarQoL D1 Physical and mental health 0.848 <0.001 0.872 0.898
SarQoL D2 Locomotion 0.911 <0.001 0.874
SarQoL D3 Body composition 0.779 <0.001 0.874
SarQoL D4 Functionality 0.915 <0.001 0.861
SarQoL D5 Activities of daily living 0.880 <0.001 0.875
SarQoL D6 Leisure activities 0.389 0.006 0.912
SarQoL D7 Fears 0.587 <0.001 0.901

All values are Spearman correlation coefficients.

Table 6.
Convergent and divergent construct validity, and correlation with overall SarQoL score
Complete sample (n=49)
Probably sarcopenic sample (n=28)
r p-value r p-value
Convergent validity
 EQ-5D Mobility -0.794 <0.001 -0.793 <0.001
 EQ-5D Usual activities -0.677 <0.001 -0.605 0.001
 SF-36 PCS 0.833 <0.001 0.869 <0.001
 EQ-VAS 0.466 0.001 0.599 0.001
Divergent validity
 SF-36 MCS 0.295 0.039 0.177 0.367
 EQ-5D Self-care -0.632 <0.001 -0.700 <0.001
 EQ-5D Pain/discomfort -0.650 <0.001 -0.684 <0.001
 EQ-5D Anxiety/depression -0.454 0.001 -0.423 0.025

All correlation coefficients obtained using Spearman method.

EQ-5D, EuroQoL 5-dimension; PCS, physical component summary; MCS, mental component summary; VAS, visual analog scale.

Table 7.
Test-retest reliability in the complete sample
Complete sample (n=50)
Probably sarcopenic sample (n=28)
ICC 95% CI ICC 95% CI
SarQoL D1 Physical and mental health 0.992 0.985–0.995 0.991 0.980–0.996
SarQoL D2 Locomotion 0.995 0.990–0.997 0.994 0.988–0.997
SarQoL D3 Body composition 0.990 0.982–0.994 0.996 0.991–0.998
SarQoL D4 Functionality 0.986 0.976–0.992 0.994 0.988–0.997
SarQoL D5 Activities of daily living 0.995 0.991–0.997 0.995 0.990–0.998
SarQoL D6 Leisure activities 0.950 0.913–0.971 0.912 0.821–0.958
SarQoL D7 Fears 0.933 0.884–0.961 0.897 0.791–0.951
SarQol Overall score 0.997 0.994–0.998 0.998 0.995–0.999
SF-36 PCS 0.966 0.940–0.980 0.970 0.937–0.986
SF-36 MCS 0.905 0.838–0.945 0.940 0.876–0.972
EQ-VAS 0.829 0.714–0.948 0.876 0.749–0.941

ICC, intra-class correlation coefficient; CI, confidence interval; PCS, physical component summary; MCS, mental component summary; VAS, visual analog scale.


1. Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, et al. Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int 2012;23:1839–48.
crossref pmid pdf
2. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755–63.
crossref pmid pdf
3. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:16–31.
crossref pmid pdf
4. Janssen I. Influence of sarcopenia on the development of physical disability: the cardiovascular health study. J Am Geriatr Soc 2006;54:56–62.
crossref pmid
5. Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing 2015;44:960–6.
crossref pmid pmc pdf
6. Beaudart C, Biver E, Reginster JY, Rizzoli R, Rolland Y, Bautmans I, et al. Validation of the SarQoL, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle 2017;8:238–44.
crossref pmid
7. Beaudart C, Edwards M, Moss C, Reginster JY, Moon R, Parsons C, et al. English translation and validation of the SarQoL, a quality of life questionnaire specific for sarcopenia. Age Ageing 2017;46:271–6.
crossref pmid pmc pdf
8. Geerinck A, Scheppers A, Beaudart C, Bruyere O, Vandenbussche W, Bautmans R, et al. Translation and validation of the Dutch SarQoL, a quality of life questionnaire specific to sarcopenia. J Musculoskelet Neuronal Interact 2018;18:463–72.
pmid pmc
9. Gasparik AI, Mihai G, Beaudart C, Bruyere O, Pop RM, Reginster JY, et al. Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia. Arch Osteoporos 2017;12:103.
crossref pmid pdf
10. Konstantynowicz J, Abramowicz P, Glinkowski W, Taranta E, Marcinowicz L, Dymitrowicz M, Reginster JY, Bruyere O, Beaudart C. Polish Validation of the SarQoL, a Quality of Life Questionnaire Specific to Sarcopenia. J Clin Med 2018;7:323.
crossref pmid pmc
11. Hodinka L, Vereckei E, Gasparik AI. Sarcopenia and quality of life: the validated Hungarian translation of the Sarcopenia Quality of Life (SarQoL) questionnaire. Orv Hetil 2018;159:1483–6.
crossref pmid
12. Safonova YA, Lesnyak OM, Baranova IA, Suleimanova AK, Zotkin EG. Russian translation and validation of SarQoL – quality of life questionnaire for patients with sarcopenia. Rheumatol Sci Pract 2019;57:38–45.
13. Tsekoura M, Billis E, Gliatis J, Tsepis E, Matzaroglou C, Sakkas GK, et al. Cross cultural adaptation of the Greek sarcopenia quality of life (SarQoL) questionnaire. Disabil Rehabil 2020;42:1006–12.
crossref pmid
14. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000;25:3186–91.
crossref pmid
15. Locquet M, Beaudart C, Reginster JY, Petermans J, Bruyere O. Comparison of the performance of five screening methods for sarcopenia. Clin Epidemiol 2017;10:71–82.
crossref pmid pmc
16. Ishii S, Tanaka T, Shibasaki K, Ouchi Y, Kikutani T, Higashiguchi T, et al. Development of a simple screening test for sarcopenia in older adults. Geriatr Gerontol Int 2014;14 Suppl 1:93–101.
crossref pmid
17. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60:34–42.
crossref pmid
18. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297–334.
crossref pdf
19. Syddall HE, Martin HJ, Harwood RH, Cooper C, Aihie Sayer A. The SF-36: a simple, effective measure of mobility-disability for epidemiological studies. J Nutr Health Aging 2009;13:57–62.
crossref pmid pmc pdf
20. Feshchenko YI, Mostovoy YM, Babiychuk YV. The procedure of adaptation of international quality of life questionnaire MOS SF-36 in Ukraine: the experience of administration in asthma patients. Ukrainian Pulm Mag 2002;3:9–11.

21. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337–43.
crossref pmid
22. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
crossref pmid pmc pdf
23. EuroQol Group. EQ-5D-5L: Ukrainian version for Ukraine [Internet]. Rotterdam, The Netherlands: EuroQol Group; c2010 [cited 2020 May 23]. Available from:

24. State Statistics Service of Ukraine. Population statistics of Ukraine [Internet]. Kyiv, Ukraine: State Statistics Service of Ukraine; c2019 [cited 2020 May 23]. Available from:

25. Alekna V, Kilaite J, Tamulaitiene M, Geerinck A, Mastaviciute A, Bruyere O, et al. Validation of the Lithuanian version of sarcopenia-specific quality of life questionnaire (SarQoL). Eur Geriatr Med 2019;10:761–7.
crossref pmid pdf
26. Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ 2011;2:53–5.
crossref pmid pmc
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 10 Web of Science
  • 10 Crossref
  • 10 Scopus
  • 5,189 View
  • 86 Download
Related articles in
Ann Geriatr Med Res

Article Category

Browse all articles >


Browse all articles >

Editorial Office
#401 Yuksam Hyundai Venturetel, 20, Teheran-ro 25-gil, Gangnam-gu, Seoul 06132, Korea
Tel: +82-2-2269-1039    Fax: +82-2-2269-1040    E-mail:                

Copyright © 2024 by Korean Geriatrics Society.

Developed in M2PI

Close layer
prev next